Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Triple-negative breast cancer (TNBC) is not a unique disease, encompassing multiple
entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite …

As the field of translational 'omics has progressed, refined classifiers at both genomic and
proteomic levels have emerged to decipher the heterogeneity of breast cancer in a clinically …

Breast cancer risk associated with germline likely pathogenic/pathogenic variants (PV)
varies by gene, often by penetrance (high> 50% or moderate 20–50%), and specific locus …

Triple negative breast cancer (TNBC) is an aggressive breast cancer with historically poor
outcomes, primarily due to the lack of effective targeted therapies. The tumor molecular …

BRCA1/BRCA2 genes play a central role in DNA repair and their mutations increase
sensitivity to DNA-damaging agents. There are conflicting data regarding the prognostic …

Breast cancer susceptibility gene 1 (BRCA1) is a tumor suppressor gene, which is mainly
involved in the repair of DNA damage, cell cycle regulation, maintenance of genome …

Approximately 5–10% of all breast cancer (BC) cases are caused by germline pathogenic
variants (GPVs) in various cancer predisposition genes (CPGs). The most common …

Due to the lack of definitive hormone receptors, triple negative breast cancer (TNBC)
patients receive little clinical benefit from endocrine or molecular targeted therapies, leading …

Highlights•Breast cancer in young women encompasses unique treatment and survivorship
considerations.•Fertility, ovarian function suppression and premature menopause are major …